
Kwan Soo Byun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9111493/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. Scientific Reports, 2017, 7, 3710.	1.6	170
2	Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation. PLoS Medicine, 2014, 11, e1001770.	3.9	117
3	Hepatolithiasis and intrahepatic cholangiocarcinoma: A review. World Journal of Gastroenterology, 2015, 21, 13418.	1.4	95
4	Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. Clinical and Molecular Hepatology, 2018, 24, 319-330.	4.5	88
5	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut, 2016, 65, 1042-1051.	6.1	76
6	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut, 2016, 65, 852-860.	6.1	70
7	Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2015, 21, 12787.	1.4	51
8	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 467-474.	1.4	47
9	Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma. Gut and Liver, 2014, 8, 177-185.	1.4	40
10	Monotherapy with tenofovir disoproxil fumarate for multiple drugâ€resistant chronic hepatitis B: 3â€year trial. Hepatology, 2017, 66, 772-783.	3.6	37
11	Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Scientific Reports, 2021, 11, 14639.	1.6	37
12	An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Journal of Korean Medical Science, 2017, 32, 212.	1.1	34
13	Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut and Liver, 2021, 15, 284-294.	1.4	33
14	Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Clinical Gastroenterology and Hepatology, 2022, 20, 427-437.e5.	2.4	33
15	CX3CR1 differentiates F4/80low monocytes into pro-inflammatory F4/80high macrophages in the liver. Scientific Reports, 2018, 8, 15076.	1.6	31
16	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. Journal of Hepatology, 2019, 71, 35-44.	1.8	29
17	Detection of hepatitis A viral RNA in sera of patients with acute hepatitis A. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 1043-1047.	1.4	28
18	Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1838-1842.	1.4	25

KWAN SOO BYUN

#	Article	IF	CITATIONS
19	The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?. Liver International, 2016, 36, 445-453.	1.9	22
20	Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clinical and Molecular Hepatology, 2016, 22, 382-389.	4.5	19
21	Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review. Clinical and Molecular Hepatology, 2017, 23, 340-346.	4.5	19
22	Clinical Characteristics and Outcomes of Acute Hepatitis A in Korea: A Nationwide Multicenter Study. Journal of Korean Medical Science, 2014, 29, 248.	1.1	18
23	Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis. Gut and Liver, 2021, 15, 599-605.	1.4	18
24	Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine Nâ€acetylâ€Ĵ²â€Dâ€glucosaminidase. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 234-240.	1.4	17
25	The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma. Gut and Liver, 2015, 9, 224-230.	1.4	17
26	Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery. Medicine (United States), 2019, 98, e17277.	0.4	16
27	Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2020, 11, e00157.	1.3	16
28	Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. BMC Gastroenterology, 2021, 21, 258.	0.8	14
29	Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. Gut and Liver, 2018, 12, 94-101.	1.4	14
30	Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure. Gut and Liver, 2014, 8, 64-69.	1.4	13
31	Determinants of reâ€compensation in patients with hepatitis B virusâ€related decompensated cirrhosis starting antiviral therapy. Alimentary Pharmacology and Therapeutics, 2022, 55, 83-96.	1.9	13
32	Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation?. Hepatology International, 2021, 15, 934-945.	1.9	11
33	Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. Journal of Clinical Medicine, 2021, 10, 1840.	1.0	11
34	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. Gut and Liver, 2021, 15, 420-429.	1.4	11
35	Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clinical and Molecular Hepatology, 2017, 23, 331-339.	4.5	11
36	Cyanoacrylate injection versus band ligation for bleeding from cardiac varices along the lesser curvature of the stomach. Clinical and Molecular Hepatology, 2016, 22, 487-494.	4.5	10

KWAN SOO BYUN

#	Article	IF	CITATIONS
37	Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study. Hepatology International, 2012, 6, 505-510.	1.9	9
38	Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. Journal of Medical Virology, 2017, 89, 849-856.	2.5	9
39	Changes in Cardiac Varices and Their Clinical Significance after Eradication of Esophageal Varices by Band Ligation. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-9.	0.8	8
40	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer, 2019, 19, 363.	1.1	8
41	How can we improve the performance of Model for Endâ€Stage Liver Disease sodium score in patients with hepatitis B virusâ€related decompensated liver cirrhosis commencing antiviral treatment?. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1641-1648.	1.4	7
42	<i>Lens culinaris</i> agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 4687-4696.	1.4	6
43	Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. PLoS ONE, 2021, 16, e0255822.	1.1	5
44	Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography. Gut and Liver, 2020, 14, 117-124.	1.4	5
45	MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology International, 2022, 16, 316-324.	1.9	5
46	Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores. Journal of Korean Medical Science, 2020, 35, e129.	1.1	4
47	Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. Journal of Clinical Medicine, 2020, 9, 323.	1.0	3
48	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. Korean Journal of Internal Medicine, 2020, 35, 1346-1353.	0.7	3
49	The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 208-214.	1.4	2
50	Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome. Clinical and Molecular Hepatology, 2021, 27, 463-473.	4.5	2
51	Placement of a Covered Self-expandable Nitinol Stent for Bile Duct Stricture that was Caused by Ischemic Injury after Transcatheter Arterial Chemoembolization in a Patient with Hepatocellular Carcinoma: A Case Report. Journal of the Korean Radiological Society, 2008, 59, 241.	0.0	0
52	Factors Affecting Complete Small Bowel Study and Diagnostic Yield in MiroCam® Capsule Endoscopy. Intestinal Research, 2011, 9, 27.	1.0	0
53	An Efficacy Evaluation of the Oral Administration Metadoxine in Korean Alcoholic Liver Patients: a Randomized, Placebo-Controlled Trial. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 1998, 6, 183.	0.1	0